1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice
    Journal Article

    Geer, E. B.; Sisco, J.; Adelman, D. T.; Ludlam, W. H.; Haviv, A.; Liu, S.; Mathias, S. D.; Gelbaum, D.; Shi, L.
    BMC Endocrine Disorders (2020)

    Fulltext@MSK | Save
  • Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study
    Journal Article

    Ikeda, T.; Takemoto, S.; Senju, H.; Gyotoku, H.; Taniguchi, H.; Shimada, M.; Dotsu, Y.; Umeyama, Y.; Tomono, H.; Kitazaki, T.; more...
    Thoracic Cancer (2020)

    Fulltext@MSK | Save
  • Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: A randomized, open-label, multicenter, phase 2 study (CENTAURUS)
    Journal Article

    Landgren, C. O.; Chari, A.; Cohen, Y. C.; Spencer, A.; Voorhees, P.; Estell, J. A.; Sandhu, I.; Jenner, M. W.; Williams, C.; Cavo, M.; more...
    Leukemia (2020)

    Fulltext@MSK | Save
  • Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
    Journal Article

    Pal, S. K.; McDermott, D. F.; Atkins, M. B.; Escudier, B.; Rini, B. I.; Motzer, R. J.; Fong, L.; Joseph, R. W.; Oudard, S.; Ravaud, A.; more...
    BJU International (2020)

    Fulltext@MSK | Save
  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study
    Journal Article

    Dimopoulos, M.; Quach, H.; Mateos, M. V.; Landgren, O.; Leleu, X.; Siegel, D.; Weisel, K.; Yang, H.; Klippel, Z.; Zahlten-Kumeli, A.; more...
    Lancet (2020)

    Fulltext@MSK | Save
  • The emerging role of antibody-drug conjugates in urothelial carcinoma
    Review

    Lattanzi, M.; Rosenberg, J. E.
    Expert Review of Anticancer Therapy (2020)

    Fulltext@MSK | Save
  • Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: Results from TAGS
    Journal Article

    Tabernero, J.; Alsina, M.; Shitara, K.; Doi, T.; Dvorkin, M.; Mansoor, W.; Arkenau, H. T.; Prokharau, A.; Ghidini, M.; Faustino, C.; more...
    Gastric Cancer (2020)

    Fulltext@MSK | Save
  • The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma
    Journal Article

    Fowler, N. H.; Nastoupil, L.; De Vos, S.; Knapp, M.; Flinn, I. W.; Chen, R.; Advani, R. H.; Bhatia, S.; Martin, P.; Mena, R.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Consensus recommendations for management and counseling of adverse events associated with lorlatinib: A guide for healthcare practitioners
    Guidelines

    Reed, M.; Rosales, A. L. S.; Chioda, M. D.; Parker, L.; Devgan, G.; Kettle, J.
    Advances in Therapy (2020)

    Fulltext@MSK | Save
  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
    Journal Article

    Goldberg, A. D.; Atallah, E.; Rizzieri, D.; Walter, R. B.; Chung, K. Y.; Spira, A.; Stock, W.; Tallman, M. S.; Cruz, H. G.; Boni, J.; more...
    Leukemia Research (2020)

    Fulltext@MSK | Save